The Bottom Line GLP-1 medications are no longer just weight-loss drugs. They are anti-inflammatory, metabolically active medications that, for the right patients, can meaningfully improve arthritis and autoimmune disease not by replacing your DMARDs or biologics, but by making them work better and protecting your heart along the way
Metformin reduces blood sugar and increases insulin sensitivity by lowering the amount of glucose released into the bloodstream and increasing glucose uptake in skeletal muscle cells (18)
Biomarker-driven personalization Matching the right drug to the right patient One of the most exciting developments is the use of biomarkers, measurable biological indicators, to predict how a patient will respond to therapy
The drug remains in Phase 3 clinical trials (see ClinicalTrials
20 ADMA is an endogenous nitric oxide synthase (NOS) inhibitor that can significantly reduce the synthesis of vasodilator NO, leading to the development of cardiovascular disease
